tiprankstipranks
Travere Therapeutics price target raised to $44 from $42 at JPMorgan
PremiumThe FlyTravere Therapeutics price target raised to $44 from $42 at JPMorgan
1M ago
Travere Therapeutics price target raised to $35 from $31 at Citi
Premium
The Fly
Travere Therapeutics price target raised to $35 from $31 at Citi
1M ago
Travere Therapeutics: Strong Growth Potential and Strategic Advancements Justify Buy Rating
Premium
Ratings
Travere Therapeutics: Strong Growth Potential and Strategic Advancements Justify Buy Rating
1M ago
Closing Bell Movers: Booking gains 3%, Akamai down 8% on earnings
PremiumThe FlyClosing Bell Movers: Booking gains 3%, Akamai down 8% on earnings
1M ago
Is TVTX a Buy, Before Earnings?
Premium
Pre-Earnings
Is TVTX a Buy, Before Earnings?
1M ago
Travere Therapeutics price target raised to $47 from $45 at Guggenheim
Premium
The Fly
Travere Therapeutics price target raised to $47 from $45 at Guggenheim
2M ago
Wells bullish on Travere Therapeutics, sees 30% of upside on submission plans
PremiumThe FlyWells bullish on Travere Therapeutics, sees 30% of upside on submission plans
2M ago
Travere Therapeutics to submit sNDA for FILSPARI in FSGS
Premium
The Fly
Travere Therapeutics to submit sNDA for FILSPARI in FSGS
2M ago
Promising Outlook for Travere Therapeutics Driven by Filspari’s Market Potential and Financial Strength
Premium
Ratings
Promising Outlook for Travere Therapeutics Driven by Filspari’s Market Potential and Financial Strength
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100